Converting Kavesa to Kale: Saudis Embrace Healthy Eating

Published Date: 02 Mar 2023

Over a long lunch of meat and rice, Asim al-Shammari recently turned to the sight of bites from restaurants he himself said were affected by Saudi anti-corruption laws.

Read Full News

Latest News

Study shows Ozempic could help dialysis patients qualify for kidney transplants

Obesity is one of the biggest barriers preventing patients with end-stage kidney disease from receiving a life-saving kidney transplant. New research from Saint Louis University School of Medicine and SSM Health physicians ...

How do I know if my kid is worrying about food and their body too much? And what should I say?

Eating disorders are most likely to develop in young people aged between 12 and 25.

Understudied eating disorder matches anorexia, bulimia severity

A diagnosis often viewed as less serious than anorexia and bulimia—and the most common eating disorder worldwide—can cause just as much harm, a new study has found.

Popular weight-loss drugs show added heart protection for diabetes patients

Injectable weight-loss drugs can reduce the risk of serious cardiovascular events for people with type 2 diabetes. Researchers at the Technical University of Munich (TUM) and Harvard Medical School have demonstrated this ...

Diabetes drug reduced irregular heartbeat events in overweight/obese adults with AFib

People with atrial fibrillation (AFib) and obesity may have fewer episodes of AFib after ablation if they take the diabetes medication metformin in addition to standard care, according to a preliminary, late-breaking science ...

Mandatory nutrient warning labels could prevent 100,000+ obesity-related deaths

Researchers from the University of Liverpool have found that making front-of-pack nutrition labeling mandatory could significantly reduce obesity rates and save thousands of lives across England.

Todays Updates

Adjuvant Belzutifan Combo Is ‘Practice Changing’ in RCC

Adding belzutifan to standard adjuvant pembrolizumab cut the risk for recurrence or death in patients with resected clear cell renal cell carcinoma.

Todays Updates

Adjuvant Belzutifan Combo Is ‘Practice Changing’ in RCC

Adding belzutifan to standard adjuvant pembrolizumab cut the risk for recurrence or death in patients with resected clear cell renal cell carcinoma.

Latest News

Obesity is one of the biggest barriers preventing patients with end-stage kidney disease from receiving a life-saving kidney transplant. New research from Saint Louis University School of Medicine and SSM Health physicians ...

Eating disorders are most likely to develop in young people aged between 12 and 25.

A diagnosis often viewed as less serious than anorexia and bulimia—and the most common eating disorder worldwide—can cause just as much harm, a new study has found.

Injectable weight-loss drugs can reduce the risk of serious cardiovascular events for people with type 2 diabetes. Researchers at the Technical University of Munich (TUM) and Harvard Medical School have demonstrated this ...

People with atrial fibrillation (AFib) and obesity may have fewer episodes of AFib after ablation if they take the diabetes medication metformin in addition to standard care, according to a preliminary, late-breaking science ...

Researchers from the University of Liverpool have found that making front-of-pack nutrition labeling mandatory could significantly reduce obesity rates and save thousands of lives across England.

News All Time

Five reasons we shouldn't 'compliment' people who lose weight

"You look so great! Have you lost weight?"

Nearly 70% of US adults meet new definition of obesity, study finds

The prevalence of obesity in the United States could rise sharply under a definition of obesity released earlier this year by the Lancet Diabetes and Endocrinology Commission.

BMI shouldn't be the only way to assess who can access weight-loss drugs

About 1 in 3 Australian adults (32%) has a body-mass index (BMI) of 30 or above. A further 34% has a BMI of 25 or above.

Diets high in ultra-processed foods are bad for us, so why are we eating more?

Aussies eat more ultra-processed foods than ever before, with busy lifestyles and personal choices often taking the blame as casual factors.

Weight loss drug stigma shows society still holds negative attitudes towards body weight and obesity

Since Wegovy received approval as a weight loss treatment in 2021, there has been huge demand for GLP-1 drugs. These drugs reduce hunger and suppress the "food noise" that can make it difficult to lose weight.

Two in three people with chronic pain turn to comfort eating

More than two-thirds of people living with chronic pain reach for chocolate or other comfort foods to cope, with new research showing that eating offers pleasure, distraction and relief from negative emotions during pain ...

Gaps and opportunities in precision medicine approach to obesity treatment identified

A new report led by researchers at Pennington Biomedical Research Center underscores the growing potential of precision medicine to transform how obesity is prevented, diagnosed and treated, while also illuminating key gaps ...

Think your BMI reflects your health? Think again, study warns

As new Statistics Canada data reveals that two-thirds of Canadians are considered overweight or obese, researchers are urging the public and policymakers to rethink how we define and measure health—starting with one of ...

Use of weight loss drugs before bariatric surgery has soared in recent years, study finds

New research findings show a significant increase in the use of weight loss drugs among patients undergoing metabolic and bariatric surgery, signaling an evolution in the management of obesity and type 2 diabetes.

Research highlights the need for culturally specific screening tools

Despite research finding a higher prevalence of eating disorders among Aboriginal youth in Australia, new research from Edith Cowan University (ECU) published in the Journal of Eating Disorders has revealed a lack of culturally ...

Semaglutide, tirzepatide recommended as first-line treatment of obesity and most of its complications in new guidance

Semaglutide or tirzepatide should be the first line treatment for people living with obesity and most of its complications, according to a new framework for the pharmacological treatment of obesity and its complications from ...

Weight-loss surgery could help boost work productivity

A new international QUT-led study found that bariatric surgery improves work productivity and employment rates in the short term—but these gains may not last beyond five years without targeted support.

Reducing risk of eating disorders by controlling peer and family pressures

Weight-related peer teasing is a strong predictor of disordered eating behaviors in adolescents, particularly those at higher genetic risk, new research shows.

Study suggests new drug for weight loss may cause fewer side effects

A new Penn Nursing study suggests that the weight-loss drug tirzepatide may cause fewer side effects like nausea and vomiting than the drug semaglutide. This research, published in Science Advances, was conducted using preclinical ...

Weight loss treatments for people with diabetes and obesity could lower the risk of obesity-related cancers

Weight loss treatments, including medication and surgical procedures, may help lower the risk of obesity-related cancers in people with obesity and type 2 diabetes, a new study shows.

Too heavy for medical care: Over 40% of specialty clinics turn away patients weighing 465 pounds

Patients weighing 450 pounds or more face barriers and discrimination when scheduling or attending doctor visits at subspecialty practices, reports a new Northwestern Medicine study.

Recommended News For You

Bayer is transforming pharmaceutical research into women's health

Added Plinabulin Boosts OS as Later-Line Treatment for EGFR Wild-Type NSCLC

Study confirms safety and efficacy of higher-dose-per-day radiation for early-stage prostate cancer

Report: Breast cancer mortality continues three decade decline, but steeper increases in incidence for some women

More cancer cases in areas where incarceration rates are high: Study

FDA Greenlights First Engineered Cell Therapy for a Solid Tumor

Biomarker-Selected Treatment Shows Promise for Bladder Preservation in MIBC

Recommended Articles For You

Interplay of Brown Hair, Follicular Biology, and Hair Growth Inhibitors in Melanoma Pathogenesis 

A New Hope: How Procarbazine is Revolutionizing Cancer Treatment 

A Revolutionary Guide to Calculating Absolute Neutrophil Counts 

Liquid Biopsy: A Game-Changer in T-Cell Lymphoma Detection and Management 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

It has been discovered that personalized dosing in the treatment of prostate cancer improves patient outcomes.

2.

Bayer is transforming pharmaceutical research into women's health

3.

Doxorubicin-Trabectedin Strategy Boosts Survival in Challenging Sarcoma

4.

Chemo-Free Triplet Yields 68% Response Rate in Richter Transformation

5.

First-Line HCC Trial's Lenvatinib-Pembrolizumab Combo Misses Target.

1.

A Closer Look at Poorly Differentiated Carcinoma: Uncovering its Complexities

2.

Decoding Efficacy, Safety, and Future Frontiers in CAR-T Cell Therapy for Hematologic Malignancies Towards CAR-T Therapy 2025

3.

Chondroma: What it is and How it Affects Your Health 

4.

Navigating the Unknown: How to Cope with Anaplastic Thyroid Cancer

5.

What Is Carboxyhemoglobin And How Can It Affect Your Health?

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part IV

2.

Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)

3.

Should We Use DARA Up Front As First-Line Therapy in MM? - Part II

4.

Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part VI

5.

Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Final Discussion

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot